Heska (HSKA) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Heska (HSKA) Releases Quarterly  Earnings Results, Beats Estimates By $0.19 EPS

Heska (NASDAQ:HSKA) released its earnings results on Tuesday. The medical research company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.19, MarketWatch Earnings reports. The firm had revenue of $29.51 million for the quarter, compared to the consensus estimate of $35.21 million. Heska had a return on equity of 9.87% and a net margin of 4.59%.

HSKA traded down $0.25 during trading hours on Wednesday, reaching $81.62. 93,738 shares of the company’s stock traded hands, compared to its average volume of 82,419. Heska has a 52-week low of $71.50 and a 52-week high of $114.50. The stock has a market cap of $613.80 million, a P/E ratio of 57.48 and a beta of 0.73.

Several equities analysts have recently weighed in on the company. Sidoti downgraded Heska from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 26th. BidaskClub raised Heska from a “sell” rating to a “hold” rating in a research report on Wednesday, March 27th. ValuEngine downgraded Heska from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research downgraded Heska from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. Heska currently has an average rating of “Hold” and an average price target of $109.00.

In related news, COO Jason A. Napolitano sold 7,500 shares of the business’s stock in a transaction on Thursday, February 14th. The stock was sold at an average price of $97.73, for a total transaction of $732,975.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.00% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Manchester Capital Management LLC boosted its holdings in Heska by 128.6% during the 1st quarter. Manchester Capital Management LLC now owns 400 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 225 shares during the period. We Are One Seven LLC purchased a new position in Heska during the 4th quarter valued at $86,000. LS Investment Advisors LLC boosted its holdings in Heska by 30.1% during the 4th quarter. LS Investment Advisors LLC now owns 1,133 shares of the medical research company’s stock valued at $98,000 after acquiring an additional 262 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Heska by 47,400.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,425 shares of the medical research company’s stock valued at $121,000 after acquiring an additional 1,422 shares during the period. Finally, Bank of Montreal Can boosted its holdings in Heska by 11.7% during the 4th quarter. Bank of Montreal Can now owns 1,876 shares of the medical research company’s stock valued at $162,000 after acquiring an additional 196 shares during the period. Institutional investors own 83.03% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Read More: Moving Average (MA)

Related posts

Leave a Comment